Triple-Drug attack shows promise against Hard-to-Treat leukemia
Disease control
Ongoing
This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the safest dose and see if the combination can make…
Phase: PHASE1, PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated May 12, 2026 13:43 UTC